🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“The regulatory approval of sotorasib represents a major landmark for patients with KRAS G12C-mutated lung cancer,” says Dr. Ferdinandos Skoulidis of the now FDA-approved targeted therapy drug that's helped trial participant Steve Castellaw. bit.ly/32REa9W #EndCancer

This seems like a good time to finally join twitter. On Friday 28th of May 2021 the FDA approved the first ever direct KRAS G12C inhibitor #sotorasib for patients with advanced KRAS p.G12C mutant lung cancer. After nearly 4 decades a truly historic milestone.

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10…

A big thank you to all patients and their families, clinical trial personnel and colleagues for making the practice changing CodeBreaK100 clinical trial possible. #ASCO2021 #KRAS #MDAndersonNews #Sotorasib

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10… #ASCO2021 #KRAS #MDAndersonNews #Sotorasib

From the November issue: Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-mutant NSCLC bit.ly/4einxFv haniel.araujo, Ximo Pechuan-Jorge, PhD, Teng Zhou, Ferdinandos Skoulidis, and colleagues MD Anderson Cancer Center